Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Jan;15(1):121-8.
doi: 10.1038/aja.2012.102. Epub 2012 Dec 10.

Silodosin is effective for treatment of LUTS in men with BPH: a systematic review

Hui Ding  1 , Wan Du, Zi-Zhen Hou, Han-Zhang Wang, Zhi-Ping Wang
Affiliations
Meta-Analysis

Silodosin is effective for treatment of LUTS in men with BPH: a systematic review

Hui Ding et al. Asian J Androl. 2013 Jan.

Abstract

The aim of this study was to systematically review the evidence on the efficacy and safety of silodosin treatments on lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH) from randomized controlled trials. We searched PubMed (1966-December 2011), Embase (1974-December 2011) and the Cochrane Library Database (2011, Issue 12). The assessed outcome measures were the change from baseline for the International Prostate Symptom Score (IPSS), quality of life (QoL) score, peak urine maximum flow rate (Q(max)), QoL related to urinary symptoms and adverse effects. Two authors independently assessed the study quality and extracted data. All data were analysed using RevMan 5.1. The meta-analysis included four randomized controlled trials with a total of 2504 patients. The study durations were each 12 weeks. At the follow-up end points, the pooled results showed that the change from baseline for the silodosin group was significantly higher than the placebo group for the IPSS, QoL score and Q(max)(mean difference (MD)=-2.78, P<0.00001; MD=-0.42, P=0.004; MD=1.17, P<0.00001,respectively) and patients felt more satisfied with QoL related to urinary symptoms in the silodosin group than the placebo group. Ejaculation disorder was the most commonly reported adverse effect. The pooled results also showed that the silodosin group was superior to the 0.2 mg tamsulosin group with respect to the IPSS and QoL score (IPSS: MD=-1.14, P=0.02; QoL score: MD=-0.26, P=0.02) and inferior to the 0.2 mg tamsulosin group with respect to Q(max) (MD=-0.85, P=0.01). In contrast, there was no significant difference in the incidence of ejaculation disorder and dizziness between the silodosin and 0.2 mg tamsulosin groups. The current meta-analysis suggested that silodosin is an effective therapy for LUTS in men with BPH and is not inferior to 0.2 mg tamsulosin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of the procedure for selecting randomised controlled trials (RCTs) for analysis.
Figure 2
Figure 2
Results of the meta-analysis on the change from baseline for the IPSS and QoL score (silodosin versus placebo). IPSS, International Prostate Symptom Score; QoL, quality of life.
Figure 3
Figure 3
Results of the meta-analysis on the change from baseline for Qmax (silodosin versus placebo). Qmax, peak urine maximum flow rate.
Figure 4
Figure 4
Results of the meta-analysis on the quality of life related to urinary symptoms (silodosin versus placebo).
Figure 5
Figure 5
Results of the meta-analysis on the adverse effects (silodosin versus placebo).
Figure 6
Figure 6
Results of the meta-analysis on the change from baseline for the IPSS and QoL score (silodosin versus tamsulosin). IPSS, International Prostate Symptom Score; QoL, quality of life.
Figure 7
Figure 7
Results of the meta-analysis on the change from baseline for Qmax (silodosin versus tamsulosin). Qmax, peak urine maximum flow rate.
Figure 8
Figure 8
Results of the meta-analysis on the adverse effects (silodosin versus tamsulosin).
See this image and copyright information in PMC

References

    1. Chapple C. Medical treatment for benign prostatic hyperplasia. BMJ. 1992;304:1198–9. - PMC - PubMed
    1. McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). Clin Evid (Online) 2011;pii:1801. - PMC - PubMed
    1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–9. - PubMed
    1. Trueman P, Hood SC, Nayak US, Mrazek MF. Prevalence of lower urinary tract symptoms and self-reported diagnosed ‘benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK. BJU Int. 1999;83:410–5. - PubMed
    1. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, et al. Arnhem; EAU; 2011. Guidelines on the Treatment of Non-neurogenic Male LUTS; pp. 8–12.

Publication types